Literature DB >> 29794145

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.

Christian Winther Eskelund1,2, Alexandra Albertsson-Lindblad3, Arne Kolstad4, Anna Laurell5, Riikka Räty6, Lone Bredo Pedersen1, Christian Hartmann Geisler1, Mats Jerkeman3, Kirsten Grønbæk7,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29794145      PMCID： PMC6278958          DOI： 10.3324/haematol.2018.194399

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.

Authors:  Anna Abrahamsson; Alexandra Albertsson-Lindblad; Peter N Brown; Stefanie Baumgartner-Wennerholm; Lars M Pedersen; Francesco D'Amore; Herman Nilsson-Ehle; Paw Jensen; Michael Pedersen; Christian H Geisler; Mats Jerkeman
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

2.  Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.

Authors:  Alexandra Albertsson-Lindblad; Arne Kolstad; Anna Laurell; Riikka Räty; Kirsten Grønbæk; Jan Sundberg; Lone Bredo Pedersen; Elisabeth Ralfkiær; Marja-Liisa Karjalainen-Lindsberg; Christer Sundström; Mats Ehinger; Christian Geisler; Mats Jerkeman
Journal:  Blood       Date:  2016-06-27       Impact factor: 22.113

3.  Impact of TP53 mutation and 17p deletion in mantle cell lymphoma.

Authors:  A M Halldórsdóttir; A Lundin; F Murray; L Mansouri; S Knuutila; C Sundström; A Laurell; H Ehrencrona; B Sander; R Rosenquist
Journal:  Leukemia       Date:  2011-07-01       Impact factor: 11.528

4.  Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.

Authors:  Eva Hoster; Andreas Rosenwald; Françoise Berger; Heinz-Wolfram Bernd; Sylvia Hartmann; Christoph Loddenkemper; Thomas F E Barth; Nicole Brousse; Stefano Pileri; Grzegorz Rymkiewicz; Roman Kodet; Stephan Stilgenbauer; Roswitha Forstpointner; Catherine Thieblemont; Michael Hallek; Bertrand Coiffier; Ursula Vehling-Kaiser; Réda Bouabdallah; Lothar Kanz; Michael Pfreundschuh; Christian Schmidt; Vincent Ribrag; Wolfgang Hiddemann; Michael Unterhalt; Johanna C Kluin-Nelemans; Olivier Hermine; Martin H Dreyling; Wolfram Klapper
Journal:  J Clin Oncol       Date:  2016-02-29       Impact factor: 44.544

5.  Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  M Dreyling; C Geisler; O Hermine; H C Kluin-Nelemans; S Le Gouill; S Rule; O Shpilberg; J Walewski; M Ladetto
Journal:  Ann Oncol       Date:  2014-09       Impact factor: 32.976

6.  Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.

Authors:  Anna Maria Fink; Jasmin Bahlo; Sandra Robrecht; Othman Al-Sawaf; Ali Aldaoud; Holger Hebart; Kathleen Jentsch-Ullrich; Steffen Dörfel; Kirsten Fischer; Clemens-Martin Wendtner; Thomas Nösslinger; Paolo Ghia; Francesc Bosch; Arnon P Kater; Hartmut Döhner; Michael Kneba; Karl-Anton Kreuzer; Eugen Tausch; Stephan Stilgenbauer; Matthias Ritgen; Sebastian Böttcher; Barbara Eichhorst; Michael Hallek
Journal:  Lancet Haematol       Date:  2017-09-12       Impact factor: 18.959

7.  High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.

Authors:  Marie-Hélène Delfau-Larue; Wolfram Klapper; Françoise Berger; Fabrice Jardin; Josette Briere; Gilles Salles; Olivier Casasnovas; Pierre Feugier; Corinne Haioun; Vincent Ribrag; Catherine Thieblemont; Michael Unterhalt; Martin Dreyling; Elizabeth Macintyre; Christiane Pott; Olivier Hermine; Eva Hoster
Journal:  Blood       Date:  2015-05-28       Impact factor: 22.113

8.  Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.

Authors:  Mats Jerkeman; Christian Winther Eskelund; Martin Hutchings; Riikka Räty; Karin Fahl Wader; Anna Laurell; Helle Toldbod; Lone Bredo Pedersen; Carsten Utoft Niemann; Christina Dahl; Hanne Kuitunen; Christian H Geisler; Kirsten Grønbæk; Arne Kolstad
Journal:  Lancet Haematol       Date:  2018-01-29       Impact factor: 18.959

9.  15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.

Authors:  Christian W Eskelund; Arne Kolstad; Mats Jerkeman; Riikka Räty; Anna Laurell; Sandra Eloranta; Karin E Smedby; Simon Husby; Lone B Pedersen; Niels S Andersen; Mikael Eriksson; Eva Kimby; Hans Bentzen; Outi Kuittinen; Grete F Lauritzsen; Herman Nilsson-Ehle; Elisabeth Ralfkiaer; Mats Ehinger; Christer Sundström; Jan Delabie; Marja-Liisa Karjalainen-Lindsberg; Christopher T Workman; Christian Garde; Erkki Elonen; Peter Brown; Kirsten Grønbaek; Christian H Geisler
Journal:  Br J Haematol       Date:  2016-07-05       Impact factor: 6.998

10.  Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.

Authors:  Olivier Hermine; Eva Hoster; Jan Walewski; André Bosly; Stephan Stilgenbauer; Catherine Thieblemont; Michal Szymczyk; Reda Bouabdallah; Michael Kneba; Michael Hallek; Gilles Salles; Pierre Feugier; Vincent Ribrag; Josef Birkmann; Roswitha Forstpointner; Corinne Haioun; Mathias Hänel; René Olivier Casasnovas; Jürgen Finke; Norma Peter; Kamal Bouabdallah; Catherine Sebban; Thomas Fischer; Ulrich Dührsen; Bernd Metzner; Georg Maschmeyer; Lothar Kanz; Christian Schmidt; Richard Delarue; Nicole Brousse; Wolfram Klapper; Elizabeth Macintyre; Marie-Hélène Delfau-Larue; Christiane Pott; Wolfgang Hiddemann; Michael Unterhalt; Martin Dreyling
Journal:  Lancet       Date:  2016-06-14       Impact factor: 79.321
View more
  3 in total

1.  Association of red blood cell distribution width and outcomes in patients with mantle cell lymphoma.

Authors:  Yi Miao; Xiao-Hui Zhou; Jing-Jing Guo; Qian Sun; Ke Shi; Jia-Zhu Wu; Hua-Yuan Zhu; Li Wang; Lei Fan; Wei Xu; Jian-Yong Li
Journal:  Cancer Med       Date:  2019-04-13       Impact factor: 4.452

2.  Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT.

Authors:  Jia Wei; Min Xiao; Zekai Mao; Na Wang; Yang Cao; Yi Xiao; Fankai Meng; Weimin Sun; Ying Wang; Xingcheng Yang; Liting Chen; Yicheng Zhang; Haichuan Zhu; Shangkun Zhang; Tongcun Zhang; Jianfeng Zhou; Liang Huang
Journal:  Signal Transduct Target Ther       Date:  2022-04-11

3.  Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study.

Authors:  Seri Jeong; Yu Jin Park; Woobin Yun; Seung-Tae Lee; Jong Rak Choi; Cheolwon Suh; Jae-Cheol Jo; Hee Jeong Cha; Jee-Yeong Jeong; HeeKyung Chang; Yoon Jin Cha; Hyerim Kim; Min-Jeong Park; Wonkeun Song; Eun-Hae Cho; Eun-Goo Jeong; Junnam Lee; Yongmin Park; Yong Seok Lee; Da Jung Kim; Ho Sup Lee
Journal:  Sci Rep       Date:  2020-08-07       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.